New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
09:06 EDTMRK, ADako, Merck collaborate on companion diagnostics development
Dako, an Agilent Technologies (A) company, announced today it has entered into a master framework agreement with Merck (MRK) to develop companion diagnostic tests for oncology drugs currently in Merck's development pipeline. The market for companion diagnostics is steadily growing, as personalized medicine may improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies.
News For A;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 24, 2014
07:33 EDTMRKMerck, NewLink enter licensing, collaboration agreement for Ebola vaccine
Merck (MRK) and NewLink Genetics (NLNK) announced that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV vaccine candidate. Under the terms of the agreement, Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products. The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics. Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate. Phase I clinical trials of the rVSV-EBOV vaccine are now underway at the Walter Reed Army Institute of Research and the NIAID at the NIH. Additional Phase I studies are underway or planned to begin in the near future at clinical research centers in Switzerland, Germany, Kenya, and Gabon in a World Health Organization-coordinated effort, and in Canada by the Canadian Immunization Research Network.
07:31 EDTMRKMerck, NewLink Genetics enter into agreement for investigational Ebola vaccine
Subscribe for More Information
November 23, 2014
17:08 EDTABulls see Keysight Technologies rising 30%, Barron's says
Subscribe for More Information
November 21, 2014
07:51 EDTMRKBofA/Merrill biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 20, 2014
16:14 EDTAAgilent announces dividend of 10c per share
Agilent Technologies announced that a quarterly dividend of 10c per share of common stock will be paid on Jan. 28, 2015, to all shareholders of record as of the close of business on Jan. 6, 2015.
07:11 EDTMRKBofA/Merrill to hold a conference
Subscribe for More Information
November 19, 2014
07:52 EDTMRKInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
07:59 EDTAAgilent downgraded to Market Perform at Cowen
Subscribe for More Information
07:00 EDTAAgilent downgraded to Market Perform from Outperform at Cowen
06:39 EDTMRKAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
16:09 EDTAAgilent plans to return $500M in capital to shareholders in FY15
Subscribe for More Information
16:07 EDTAAgilent sees FY15 EPS $1.68-$1.78, consensus $1.74
Subscribe for More Information
16:06 EDTAAgilent sees Q1 EPS 39c-43c, consensus 42c
Subscribe for More Information
16:06 EDTAAgilent reports Q4 EPS 88c, consensus 89c
Subscribe for More Information
15:16 EDTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Agilent Technologies (A), consensus 89c; Jacobs Engineering (JEC), consensus 86c; Urban Outfitters (URBN), consensus 41c; Omega Protein (OME), consensus 30c.
11:55 EDTMRKMerck says IMPROVE-IT study met all primary, secondary endpoints
Merck announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN which combines simvastatin with the non-statin ZETIA -- experienced significantly fewer major cardiovascular events than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions. Merck plans to submit the data from IMPROVE-IT to the U.S. Food and Drug Administration in mid-2015 to support a new indication for reduction of major cardiovascular events for VYTORIN and ZETIA. VYTORIN and ZETIA are currently indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia. The current U.S. Prescribing Information for both products states that the effect of ezetimibe on cardiovascular morbidity and mortality, alone or incremental to statin therapy, has not been determined.
08:34 EDTMRKMerck says IMPROVE-IT met primary endpoint
Subscribe for More Information
November 16, 2014
13:26 EDTMRKMerck: KEYTRUDA showed superiority to chemotherapy for primary endpoint of PFS
Subscribe for More Information
November 14, 2014
14:53 EDTMRKCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:46 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use